Scientific article

Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection

Published inCardiovascular drugs and therapy, vol. 26, no. 3, p. 227-237
Publication date2012

We studied the role of two powerful molecular signalling mechanisms involved in the cardioprotective effect of sphingosine-1-phosphate (S1P), a major component of high density lipoprotein (HDL) against myocardial ischaemic-reperfusion injury, namely the RISK pathway (Akt/Erk), including its downstream target FOXO-1 and, the SAFE pathway (TNF/STAT-3).

  • Animals
  • Cardiotonic Agents/pharmacology/therapeutic use
  • Extracellular Signal-Regulated MAP Kinases/metabolism
  • Forkhead Transcription Factors/metabolism
  • Lysophospholipids/pharmacology/therapeutic use
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myocardial Infarction/drug therapy/metabolism/pathology
  • Myocardial Reperfusion Injury/drug therapy/metabolism/pathology
  • Proto-Oncogene Proteins c-akt/metabolism
  • STAT3 Transcription Factor/genetics/metabolism
  • Signal Transduction/drug effects
  • Sphingosine/analogs & derivatives/pharmacology/therapeutic use
  • Tumor Necrosis Factor-alpha/genetics/metabolism
Citation (ISO format)
SOMERS, Sarin J et al. Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. In: Cardiovascular drugs and therapy, 2012, vol. 26, n° 3, p. 227–237. doi: 10.1007/s10557-012-6376-2
Main files (1)
Article (Published version)
ISSN of the journal0920-3206

Technical informations

Creation10/28/2013 4:09:00 PM
First validation10/28/2013 4:09:00 PM
Update time03/14/2023 8:42:06 PM
Status update03/14/2023 8:42:06 PM
Last indexation05/02/2024 1:33:32 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack